Paradigm Biopharmaceuticals (ASX:PAR) has bolstered its international clinical presence with the activation of a new trial site in Hong Kong.
The expansion marks a milestone for the company's global Phase 3 PARA_OA_012 study, which is evaluating the efficacy of injectable pentosan polysulfate sodium in treating patients suffering from knee osteoarthritis.
The newly commissioned site, the Hong Kong Centre for Clinical Research, has already commenced patient screening under the leadership of Principal Investigator Dr Edith Lau Ming Chu.
The timing of this activation is critical as Paradigm rapidly approaches a key 50% recruitment threshold.
Reaching this halfway mark will trigger a planned interim analysis, providing vital data on the drug’s progress.
To further accelerate the momentum, the company confirmed that three additional sites in Moldova are slated for activation in the coming weeks.
The additions are designed to streamline the final enrolment phase for the 466-participant study, which measures primary outcomes based on changes in average pain levels over 112 days.
To ensure seamless integration, Paradigm's senior management team is scheduled to visit the Hong Kong facility in mid-April.
Managing Director Paul Rennie emphasised that this expansion, supported by specialist contract research organisations like NBCD and Advanced Clinical, is essential for generating the robust, diverse global data required for upcoming regulatory submissions.